CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Prokinetic, peripheral dopamine D2 receptor antagonist
Updated · Methodology
Mechanism
Darunavir is taken only with a booster, ritonavir or cobicistat. In this regimen it inhibits the elimination of drugs that depend heavily on the enzyme CYP3A, so their blood levels rise (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Domperidone is on the list of such drugs, for which high levels can cause serious or life-threatening effects (darunavir SmPC, EMA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and in vitro data suggest that drugs that markedly inhibit this enzyme may raise domperidone plasma levels (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone SmPC, AEMPS). Darunavir and domperidone have not been studied together, and the documents do not say how much domperidone levels rise (darunavir SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The adverse reactions listed for darunavir with ritonavir include prolongation of the heart-rate-corrected QT interval (QTc) on the ECG, fast heart rate, sinus bradycardia and palpitations (darunavir SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. Domperidone is on the list of drugs contraindicated with darunavir boosted with either ritonavir or cobicistat, including the tablets that combine darunavir with cobicistat (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish domperidone SmPC contraindicates domperidone with strong CYP3A4 inhibitors regardless of their own effect on the QT interval and names protease inhibitors, including ritonavir, among them (domperidone SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Before starting darunavir, read the SmPC of the booster, ritonavir or cobicistat, and check the SmPC of each concomitant drug for its metabolic pathway, interaction mechanisms, potential risks and the actions needed (darunavir SmPC, EMA). If domperidone and darunavir have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat/emtricitabina/tenofovir alafenamida, Symtuza (EU/1/17/1225), sección 4.5 (2026)– EMA, Symtuza 800 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1171225001, consultada 21.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5